Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July 7, 2026 /PRNewswire/ — Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of…
Source: prnewswire
Country: United States